On Oct. 28, 2010, Emergent BioSolutions announced it had completed the acquisition of Seatte-based Trubion Pharmaceutical for upfront consideration of $96.8 million of value and up to $38.7 million of success-based milestones, resulting in a total consideration of up to $135.5 million.

The acquisition provided Emergent with multiple, advanced stage candidates in the key disease areas of oncology and autoimmunity as well as access to novel and versatile protein therapeutic platforms. Trubion’s platforms were designed to address the limitations of monoclonal antibodies and complement Emergent’s existing antibody therapeutic capabilities.